Odefsey (Emtricitabine, Tenofovir Alafenamide, Rilpivirine)

Emtricitabine, the active ingredient in Odefsey, is a nucleoside reverse transcriptase inhibitor presented as a fixed‑dose combination tablet for oral use. It treats HIV‑1 infection in adults and adolescents when used with other antiretrovirals. GNH USA supplies Odefsey as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Odefsey as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Odefsey is a fixed‑dose antiretroviral regimen that targets the HIV‑1 replication pathway.

- HIV‑1 infection (adults and adolescents): provides a complete, once‑daily regimen that suppresses viral load when combined with other antiretrovirals. - Treatment‑naïve patients: offers a convenient single‑tablet option to achieve and maintain viral suppression. - Patients switching from other regimens: facilitates a simplified dosing schedule while maintaining efficacy.

Adverse reactions to Odefsey are reported across clinical studies and post‑marketing surveillance.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, usually transient. - Headache: mild tension‑type headache. - Fatigue: general tiredness. - Insomnia: difficulty falling or staying asleep. - Rash: mild skin erythema.

Serious or Rare Side Effects: - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Severe hypersensitivity: rash with systemic involvement, possibly Stevens‑Johnson syndrome. - Renal impairment: worsening kidney function, especially in patients with pre‑existing disease. - Bone mineral density loss: decreased bone density with long‑term use. - Lactic acidosis: rare metabolic acidosis with high lactate levels. - QT prolongation: potential cardiac rhythm disturbance.

When prescribing Odefsey, clinicians should consider several safety aspects.

- Renal function assessment: evaluate baseline kidney function before initiation. - Hepatic monitoring: check liver enzymes periodically, especially in patients with hepatitis. - Pregnancy counseling: discuss potential risks and benefits with women of childbearing potential. - Drug‑interaction review: assess concomitant medications for possible interactions. - Adherence support: emphasize the importance of daily dosing for viral suppression. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Odefsey may interact with other medicines that affect its absorption, metabolism, or excretion.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: reduce rilpivirine absorption. - Proton pump inhibitors (e.g., omeprazole): lower rilpiviri ne levels. - Rifampin and other strong CYP3A inducers: markedly decrease rilpivirine concentrations.

Moderate Interactions (Monitor Closely): - H2‑blockers (cimetidine, ranitidine): may modestly reduce rilpivirine exposure.\n- Lipid‑lowering agents (statins such as rosuvastatin): increased statin exposure due to tenofovir alafenamide. - Contraceptive hormones: potential reduction in hormonal efficacy. - Warfarin: possible alteration of INR values. - Methotrex ​